🔗 Share this article

As the US proceeds with unprecedented revisions to its vaccination recommendations, a particular individual appears in a surprising turn: Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on Covid vaccines during the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her short time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Public health authorities were set to unveil radical revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US out of alignment with much of the international standard with no evidence for benefit. The announcement has been postponed until the coming year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to lead the division this year.

A Shift at the FDA

This interim role might represent a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting some pediatric shot schedules in the US so as to align more like Denmark, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

The appointee has little discernible track record in medication creation, oversight or administrative roles, which has been typical for previous directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who led CBER have had.”

This division has an enormous portfolio at the FDA, Woodcock emphasized.

“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and every single one need to be looked after,” she said. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the position, which manages more than 5,000 staff members. “It is a massive management job, if you perform it correctly,” the former official said.

Response and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among agency officials on immunizations, a representative stated that the “inquiries rely on inaccurate presumptions”.

“Her experience is consistent with the functions of her job,” the spokesperson said, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious expedited medication authorization process that allegedly troubled her former heads. “How are these medications being selected for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

Overall, he stated, “the FDA looks to be trending towards less stringent regulations of all drugs, with the exception of vaccines.”

Established History on Immunizations

With immunizations, Dr. Høeg has a more documented, if troubling, past, Howard have noted. She published a study using non-validated crowd-sourced reports to assess the incidence of heart inflammation after Covid immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current administration included revising regulations for new vaccines and discontinuing “unnecessary” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of barring young men from obtaining COVID-19 vaccines.

“She is an thorough ideologue who starts off with her preconceived notions and tailors the evidence to accommodate the science in a extremely disingenuous, untruthful manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|